Company intelligence / Profile preview
S1P Therapeutics
Blacksburg, Virginia, United Statess1ptx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company is in preclinical stages with promising results showing that their lead SPNS2 inhibitors are less broadly immunosuppressive with fewer adverse events compared to other therapies targeting the S1P pathway[1][2]. They have received funding support such as a $100K grant from Virginia Innovation Partnership Corporation in late 2023 to advance their technology for inflammatory bowel disease treatment[5].
- Therapeutic areas
- ImmunologyNephrology
- Modalities
- Small molecule inhibitors targeting sphingosine 1-phosphate transporters
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on S1P Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S1P Therapeutics.